

**NOTICE OF CHANGE OF AUDITOR**  
**Pursuant to National Instrument 51-102 (Part 4.11)**

TO: Anton, Bryson and Schindler Chartered Professional Accountants LLP  
AND TO: KPMG LLP  
AND TO: British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

---

In accordance with National Instrument 51-102, please be advised as follows:

1. Effective June 16, 2017, Anton, Bryson and Schindler Chartered Professional Accountants LLP (the “**Former Auditor**”) resigned as auditors of InMed Pharmaceuticals Inc. (the “**Company**”) at the request of the Company.
2. KPMG LLP (the “**Successor Auditor**”) has been appointed as the Company’s successor auditors until the next annual general meeting of the Company.
3. The resignation of the Former Auditor and the appointment of the Successor Auditor was considered and recommended for approval by the Audit and Risk Committee of the Company’s Board of Directors and approved by the Company’s Board of Directors.
4. The Former Auditor’s reports on the financial statements of the Company for the two most recently completed financial years and through to the date of the Former Auditor’s resignation did not contain a modified opinion.
5. There have been no “reportable events”, as defined in National Instrument 51-102, between the Company and the Former Auditor.

**DATED** this 16<sup>th</sup> day of June, 2017.

**INMED PHARMACEUTICALS INC.**

Per: \_\_\_\_\_

Jeff Charpentier  
Chief Financial Officer